Catálogo de publicaciones - libros

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.

Incretin based therapies for type 2 diabetes mellitus are quite promising. Presently, basic research places both GIP and GLP-1 based approaches on an equal standing. Recently, there has been renewed interest into the physiology of GIP in humans, and thus it is possible that DP IV resistant GIP analogues will be administered to human diabetics, perhaps reconciling differences between clinical and pre-clinical studies. Development of injection-delivered GLP-1 derivatives continues to meet expectations as a therapeutic option for the future. Particular attention to severity of diabetes and age must be considered when examining the effectiveness of either GIP or GLP-1 based analogues in human patients. Despite some uncertainties as to the precise mediators of DP IV inhibitors, data from mouse models indicate that the beneficial effects are conveyed by the known incretin hormones. Predictions of the relative contributions of GIP and GLP-1 to the glucose lowering activity of DP IV inhibition have been made, however, experimental data is required for conclusive resolution of this point. Only specifically designed studies can answer this question using selective antagonists of either the GIP or GLP-1 receptor, alone or in combination, in conjunction with DP IV inhibitors in healthy and diabetic humans.